Importance of trough:peak ratios in treatment of blood pressure in post-myocardial infarction and heart failure settings

Journal of Human Hypertension

Volumn 11, Issue 1, 1997, Pages 39-43

  Meredith, P A ^a,b  

^a Glasgow Homeopathic Hospital   (United Kingdom)

^b WESTERN INFIRMARY   (United Kingdom)

Author keywords

24 h blood pressure control; Antihypertensive response; Heart failure; Post MI; Trough:peak ratio

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

BLOOD PRESSURE REGULATION; CONFERENCE PAPER; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART REINFARCTION; HYPERTENSION; SECONDARY PREVENTION; SUDDEN DEATH;

EID: 0030971189     PISSN: 09509240     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.jhh.1000399     Document Type: Conference Paper

References (14)

1. Schevhtman KB et al. (The Diltiazem Reinfarction Study Group): Differential risk patterns associated with 3-months as compared with 3-12 months mortality and reinfarction after non-Q-wave myocardial infarction. J Am Col Cardiol 1990; 15: 940-947.
2. Flack JM et al. (For the Multiple Risk Factor Intervention Trial Research Group): Blood pressure and mortality among men with prior myocardial infarction. Circulation 1995; 92 (9): 2437-2445.
3. Herlitz J et al. Prognosis in hypertensives with acute myocardial infarction. J Hypertens 1992; 10: 1255-1261.
4. Meredith PA, Perloff D, Mancia G, Pickering T. Blood pressure variability and its implications for antihypertensive therapy. Blood Press 1995; 4: 5-11.
5. Rose M, McMahon FG. Some problems with antihypertensive drug studies in the context of the new Guidelines. Am J Hypertens 1990; 3: 151-155.
6. Stokes GS et al. Timing of blood pressure measures in determining anomalies in duration of hypertension drug: assessment of isradipine. J Cardiovasc Pharmacol 1990; 15 (Suppl 1): S65-S69.
7. Meredith PA et al. Prediction of the antihypertensive response to enalapril. J Hypertens 1990; 8: 1085-1090.
8. Zannad F. Trandolapril: how does it differ from other angiotensin converting enzyme inhibitors? Drugs 1993; 46 (Suppl 2): 172-182.
9. Ménard J, Bellet M, Brunner HR. Clinical development of antihypertensive drugs: can we perform better? In: Laragh JH, Brenner BM (eds). Hypertension: Pathophysiology, Diagnosis & Management. 1st edn. Raven Press Limited, New York, 1990, pp 2331-2350.
10. Rudd P et al. Improved compliance measures: applications in an ambulatory hypertensive drug trial. J Clin Pharmacol Therapeut 1990; 48: 676-685.
11. Magometschnigg D. Compliance von Hypertonikern in der ärztlichen Praxis. In: Hitzenberger G (ed). 19. Symposium Teil 2: Compliance. Österreichische Arbeitsgemeinschaft für Klinische Pharmakologie: Blackwell Wissenschafts-Verlag, Wien, 1995, pp 47-54.
12. Vaur L et al. Differential effects of a 'missed dose' of trandolapril and enalapril on blood pressure control in hypertensive patients. J Cardiovasc Pharmacol 1995; 26 (1): 127-131.
13. Dahlöff B et al. STOP-Hypertension2: a prospective intervention trial of 'newer' versus 'older' treatment alternatives in old patients with hypertension. Blood Press 1993; 2 (2): 136-141.
14. Elliott HL, Meredith PA. Trough : peak ratio: clinically useful or practically irrelevant? J Hypertens 1995; 13 (3): 279-283.